HIGH-DOSAGE CO-AMOXICLAV IN A SINGLE-DOSE VERSUS 7 DAYS OF COTRIMOXAZOLE AS TREATMENT OF UNCOMPLICATED LOWER URINARY-TRACT INFECTION IN WOMEN

The efficacy and adverse event profile of a single 3.25 g dose of co-a moxiclav as treatment of acute uncomplicated lower urinary tract infec tion in women was compared with that of co-trimoxazole 960 mg bd for 7 days in a prospective, randomized, double-blind multicentre clinical trial. Of the 666 patients enrolled, 279 (144 in the co-amoxiclav grou p and 135 in the co-trimoxazole group) were eligible for evaluation of clinical and bacteriological responses. At the follow-up assessment 4 2 days after study entry, the successful clinical response rate was 73 .8% for patients who received co-amoxiclav, compared with 85.1% for pa tients given co-trimoxazole (P less than or equal to 0.05); the corres ponding rates for successful bacteriological response were 64.1% and 7 9.6% (P less than or equal to 0.05). Both treatment regimens were well -tolerated, with 15% of patients in the co amoxiclav group and 12% of patients in the co-trimoxazole group reporting adverse events (P great er than or equal to 0.05). The adverse event profiles for the two grou ps differed, gastrointestinal disturbances predominating amongst patie nts who received co-amoxiclav and rashes being commonest amongst those given co-trimoxazole.